Skip to main content
. 2023 Apr 13;25:60. doi: 10.1186/s13075-023-03036-4

Fig. 3.

Fig. 3

Association between trough plasma ozoralizumab concentration and ACR20 response at week 16. The 16-week ACR20 response rates were compared by quartile in the OHZORA trial (A) and the NATSUZORA trial (B), or stratified as above and below the boundary value, which was 1.15 µg/mL in the OHZORA trial (C) and 1.00 µg/mL in the NATSUZORA trial (D). Fisher’s exact test, *p < 0.05, **p < 0.01. ACR20 ≥ 20% improvement according to the American College of Rheumatology criteria, n.s. not significant